NewAmsterdam's experimental cholesterol drug reduces presence of Alzheimer's biomarker

Max Gelman

Senior Editor

NewAmsterdam Pharma’s stock ticked upward on Monday after a biomarker analysis of its experimental cholesterol-lowering drug showed promise in Alzheimer’s disease.

The drug, a CETP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

NewAmsterdam's experimental cholesterol drug reduces presence of Alzheimer's biomarker

Max Gelman

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Merck says its oral PCSK9 inhibitor ‘significantly’ cut cholesterol in two Phase 3 trials

Merck wins FDA approval for RSV antibody drug, making a hot market more competitive

Avidity to seek accelerated approval for FSHD drug; Axsome to run another trial

Metsera shares early data on anti-obesity amylin candidate

In a break from other biotechs, Twist Bioscience throws support behind tariffs on synthetic DNA

McKesson leads the charge in revolutionizing precision oncology in community practices

NewAms­ter­dam's ex­per­i­men­tal cho­les­terol drug re­duces pres­ence of Alzheimer's bio­mark­er

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

NewAmsterdam's experimental cholesterol drug reduces presence of Alzheimer's biomarker